Screener
Ionis Pharmaceuticals IONS Commercial — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Product sales, net | $$31,139 | $19,273 | $74,094 | 25,561 |
| Royalty revenue | 75,958 | 69,952 | 134,282 | 134,117 |
| Other commercial revenue | 11,526 | 13,531 | 18,058 | 19,246 |
| Total commercial revenue | 118,623 | 102,756 | 226,434 | 178,924 |
| Research and development revenue: | ||||
| Collaborative agreement revenue | 133,137 | 336,921 | 253,797 | 381,951 |
| WAINUA joint development revenue | 16,189 | 12,372 | 33,811 | 22,785 |
| Total research and development revenue | 149,326 | 349,293 | 287,608 | 404,736 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's commercial — revenue?
- Ionis Pharmaceuticals (IONS) reported commercial — revenue of $118.62M in Q2 2026.
- How has Ionis Pharmaceuticals's commercial — revenue changed year-over-year?
- Ionis Pharmaceuticals's commercial — revenue increased by 15.4% year-over-year, from $102.76M to $118.62M.
- What is the long-term trend for Ionis Pharmaceuticals's commercial — revenue?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's commercial — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $342.4M to $435.85M.
- What does commercial — revenue mean?
- This metric represents the total revenue generated from the sale of commercialized pharmaceutical products, excluding any taxes collected from customers. It reflects the core top-line performance of the company's marketed drug portfolio, distinct from licensing fees or research collaboration payments. This figure is a key indicator of the company's ability to successfully transition from drug discovery to sustainable commercial market penetration.
Ask your AI about Ionis Pharmaceuticals's commercial — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude